Evercore ISI Group initiated coverage on Entrada Therapeutics
$TRDA
Biotechnology: Pharmaceutical Preparations
Health Care
Evercore ISI Group initiated coverage of Entrada Therapeutics with a rating of Outperform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/6/2024 | $29.00 | Buy | ROTH MKM |
| 1/5/2024 | $22.00 | Outperform | Oppenheimer |
| 4/3/2023 | $25.00 | Buy | H.C. Wainwright |
| 11/24/2021 | Outperform | Evercore ISI Group | |
| 11/23/2021 | Outperform | Cowen & Co. | |
| 11/23/2021 | $29.00 | Neutral | Goldman Sachs |
ROTH MKM initiated coverage of Entrada Therapeutics with a rating of Buy and set a new price target of $29.00
Oppenheimer initiated coverage of Entrada Therapeutics with a rating of Outperform and set a new price target of $22.00
H.C. Wainwright initiated coverage of Entrada Therapeutics with a rating of Buy and set a new price target of $25.00
4/A - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
SCHEDULE 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)
SCHEDULE 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)
10-Q - Entrada Therapeutics, Inc. (0001689375) (Filer)
-- First patient dosed in ELEVATE-44-201 with data from first patient cohort anticipated in H1 2026 -- -- Initiated ELEVATE-45-201 and on track to dose the first patient in Q3 2025 -- -- Multiple clinical trial sites in U.K. and EU activated for ELEVATE-44-201 and ELEVATE-45-201 -- -- Leadership team expanded with the additions of Navid Khan, PhD, as Senior Vice President of Medical Affairs and Kiran Patki, MD, MSc, FFPM, as Senior Vice President of Clinical Development -- -- Cash runway expected into Q2 2027 with $354 million in cash, cash equivalents and marketable securities as of June 30, 2025 -- BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) to
BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. "We are pleased to have Dr. Radhakrishnan join the Board at this time of tremendous clinical momentum at Entrada, led by the continued advancement of our Duchenne muscular dystrophy franchise. Dr. Radhakrishnan's deep and meaningful experience in global drug development will be invaluable as we quickly advance our novel Duchenne programs into multiple patient-focused clinical trials throughout this year," said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics. "I'm honored to join the Board of Entrada
BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced that the Company granted an aggregate of 23,820 restricted stock units ("RSUs") to six newly-hired non-executive employees under the Company's 2025 Inducement Equity Plan (the "Inducement Plan"), effective as of June 1, 2025. The inducement grants were previously approved by the Compensation Committee of the Company's Board of Directors, as a material inducement to the new employees' entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). One-fourth of the RSUs will vest on the one-year anniversary of the vesting commencement date, and 6.25% shall vest quart
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
-- First patient dosed in ELEVATE-44-201 with data from first patient cohort anticipated in H1 2026 -- -- Initiated ELEVATE-45-201 and on track to dose the first patient in Q3 2025 -- -- Multiple clinical trial sites in U.K. and EU activated for ELEVATE-44-201 and ELEVATE-45-201 -- -- Leadership team expanded with the additions of Navid Khan, PhD, as Senior Vice President of Medical Affairs and Kiran Patki, MD, MSc, FFPM, as Senior Vice President of Clinical Development -- -- Cash runway expected into Q2 2027 with $354 million in cash, cash equivalents and marketable securities as of June 30, 2025 -- BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) to
BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. "We are pleased to have Dr. Radhakrishnan join the Board at this time of tremendous clinical momentum at Entrada, led by the continued advancement of our Duchenne muscular dystrophy franchise. Dr. Radhakrishnan's deep and meaningful experience in global drug development will be invaluable as we quickly advance our novel Duchenne programs into multiple patient-focused clinical trials throughout this year," said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics. "I'm honored to join the Board of Entrada
āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of bone and connective tissue disorders, today announced the appointment of Dipal Doshi to its Board of Directors. Mr. Doshi currently serves as Chief Executive Officer of Entrada Therapeutics (NASDAQ:TRDA). "Dipal is a seasoned leader with significant experience setting strategy and driving the operational and commercial growth of biopharmaceutical companies," said Pankaj Bhargava, M.D., Chief Executive Officer of āshibio. "Under Dipal's leadership, Entrada has advanced its innovative pipeline of intracellular therapeutics into the clinic, completed multiple private financings,
SC 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)
SC 13D/A - Entrada Therapeutics, Inc. (0001689375) (Subject)
SC 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)